Agomab Reports Positive Phase 2a Results for Ontunisertib in Fibrostenosing Crohn’s Disease

FDA Expands RINVOQ® Indication for Inflammatory Bowel Disease

AstraZeneca Partners with Immunai in $85M AI-Driven IBD Deal

Phase 4 Study: Vedolizumab More Effective in Early Crohn’s Disease

CU Anschutz Study Links MAIT Cells to Gut Inflammation

SMC Approves TREMFYA® for Crohn’s Disease and Ulcerative Colitis

MRC Researchers Uncover Cell Mechanism Behind Crohn’s Fistulas

Numab and Kaken Partner on First-in-Class Multispecific Antibody for IBD

Chitra Karki

Senior Director, Liver/Inflammatory Diseases, Global Evidence and Outcomes Takeda Pharmaceutical

Thursday 2nd April 2026

Roundtable Discussion: Delivering Faster & More Reliable IBD Trials Using Real-World Evidence, Smarter Recruitment & Meaningful Endpoints

11:45 am

Explore innovative recruitment and retention strategies that have successfully reduced trial delays and improved reliability
Share experiences using real-world data and predictive tools to identify ideal candidates and assess the impact on response rates and trial costs
Examine how real-world evidence can be strategically applied to design endpoints in IBD trials that are clinically meaningful and aligned with regulatory and commercialization goals
Address challenges of data fragmentation in IBD research by improving access to comprehensive datasets including biomarkers, histology, and patient-reported outcomes